CagriSema's EASD 2026 Data: Mechanistic Depth Without Pivotal Anchors

CagriSema Shows Brain, Organ, and Bone Benefits in Obesity and Diabetes

Novo Nordisk presented new data on its investigational drug CagriSema at the European Association for the Study of Diabetes (EASD) Annual Meeting 2026, highlighting its multi-faceted impact beyond just weight loss. A 52-week fMRI study in adults with overweight or obesity demonstrated that CagriSema modified brain responses to high-calorie food cues, significantly reducing 'food noise', cravings, and hunger, leading to a 22.4% body weight reduction. Additionally, a diabetes MRI sub-study from the phase 3a REIMAGINE 1 trial showed significant reductions in abdominal, liver, and pancreas fat, alongside a 14.3% weight loss in early type 2 diabetes patients. A post hoc analysis of the phase 3 REIMAGINE 2 trial also indicated maintained bone health with a 14.2% weight reduction in type 2 diabetes patients.

• A 52-week functional magnetic resonance imaging (fMRI) study in adults with overweight or obesity revealed that CagriSema modified brain responses to high-calorie food cues in regions associated with cravings, reward, and behavioral control. This led to substantial improvements in eating behavior, including a reduction in 'food noise', cravings, hunger, and food-related thoughts, culminating in a 22.4% body weight reduction versus placebo at 52 weeks (estimated treatment difference, p<0.0001).
• Data from the REIMAGINE 1 diabetes MRI sub-study showed that CagriSema 2.4 mg/2.4 mg produced significant reductions in fat in the abdomen and around the liver and pancreas in adults with early type 2 diabetes. These metabolic improvements were observed alongside a 14.3% body-weight reduction at week 40, suggesting a direct impact on ectopic fat, a key contributor to insulin resistance and type 2 diabetes progression.
• A post hoc analysis of bone markers from the phase 3 REIMAGINE 2 trial in adults with inadequately controlled type 2 diabetes indicated signs of healthy balance in bone maintenance. This finding provides preliminary reassurance regarding bone changes, despite a substantial 14.2% body-weight reduction achieved with CagriSema 2.4 mg/2.4 mg at week 68, addressing concerns about bone health during significant weight loss.

CagriSema: Addressing Food Noise and Organ Fat Beyond Weight Loss

Current pharmacological and surgical approaches to overweight, obesity, and type 2 diabetes have delivered meaningful clinical advances, yet several structural limitations constrain their long-term effectiveness. The evidence base highlights recurring challenges spanning treatment durability, population-specific risks, metabolic adaptation, and disease progression.

• Weight regain following GLP-1 receptor agonist discontinuation is substantial and follows a front-loaded trajectory, with a large proportion occurring during the early post-cessation period. This pattern reflects restoration of appetite after withdrawal of pharmacological GLP-1 signalling, compensatory increases in orexigenic hormones such as ghrelin, and alterations in incretin balance. Whether structured tapering strategies can successfully facilitate treatment discontinuation remains unknown and requires prospective evaluation.

• Risks in older adults with sarcopenic obesity represent a distinct and underaddressed challenge. GLP-1 receptor agonists and dual GIP/GLP-1 receptor agonists — including liraglutide, semaglutide, and tirzepatide — have not been exhaustively evaluated in older adults with sarcopenic obesity. These medications carry a risk of loss of muscle mass and an increased rate of adverse events in this population, requiring clinicians to carefully weigh potential benefits against risks.

• Gastrointestinal adverse event burden varies significantly across GLP-1 receptor agonist classes and limits tolerability. In a Bayesian network meta-analysis of 48 randomised controlled trials involving 27,729 participants, the overall incidence of gastrointestinal adverse events was 11.66%, with nausea being the most frequent at 21.49%. Tirzepatide exhibited the highest risk of nausea and diarrhea, while semaglutide demonstrated a significantly higher risk of diarrhea compared to other GLP-1 receptor agonists.

• Metabolic adaptation counteracts sustained weight loss through mechanisms independent of changes in fat-free mass. Adaptive thermogenesis during negative energy balance is directed towards energy sparing, with low leptin levels during maintenance of reduced weight keeping energy expenditure low. In exercise-induced weight loss, those who experienced a downregulation in resting energy expenditure also experienced an upregulation in energy intake, indicating that the adaptive metabolic response influences both physiological and behavioural components of energy balance.

• Progressive beta-cell failure in type 2 diabetes undermines the durability of glucose-lowering interventions. Irrespective of underlying levels of insulin resistance, the progressive failure and loss of beta-cells are ultimately responsible for the onset of frank type 2 diabetes, driven by mechanisms including glucose and lipid toxicity, increased secretory demand, amyloid deposition, and altered cytokine levels. Most patients with type 2 diabetes will experience a gradual loss of glycaemic control despite intervention with effective oral glucose-lowering agents.

• Bariatric surgery carries a significant long-term complication burden that requires sustained clinical management. Late postoperative complications include dumping syndrome, marginal ulcers, and nutritional and vitamin deficiencies, some of which can result in neurologic disorders. Patients require daily multivitamins with minerals, vitamin D, and calcium, and must consume 1 to 1.5 g of protein per kilogram of ideal body weight daily, with regular monitoring of vitamin levels to prevent deficiencies.

CagriSema's Brain, Organ, and Bone Health Data from EASD 2026

Recent clinical evidence across overweight, obesity, and type 2 diabetes highlights the expanding role of GLP-1 receptor agonists and dual GIP/GLP-1 agonists, with tirzepatide and semaglutide demonstrating substantial weight reduction and manageable, predominantly gastrointestinal safety profiles across diverse patient populations.

CagriSema's Position in the Evolving Obesity and T2D Landscape

Tirzepatide, a dual GIP/GLP-1 receptor agonist, has emerged as a benchmark for comparing investigational and standard-of-care therapies across obesity and type 2 diabetes (T2DM). In patients with overweight or obesity without diabetes, a meta-analysis of six randomized controlled trials demonstrated that tirzepatide produced a mean percentage body weight reduction of -16.32% (95% CI: -18.35 to -14.29) and an absolute weight reduction of -13.95 kg (-18.83 to -9.07) versus placebo, alongside significant reductions in BMI (-5.89 kg/m²; -8.97 to -2.81) and waist circumference (-12.31 cm; -13.93 to -10.68). In T2DM, a network meta-analysis found tirzepatide 15 mg superior to once-weekly insulin formulations in HbA1c reduction (MD -1.27; 95% CI -1.49 to -1.00) and body weight reduction (MD -12.13 kg; 95% CI -13.98 to -10.27). A systematic analysis of placebo-controlled phase 3/4 trials further confirmed that HbA1c reductions ranged from -0.63% with lixisenatide 20 µg to -1.79% with tirzepatide 15 mg, and weight reductions from -0.75 kg to -9.65 kg across incretin mimetics — with tirzepatide consistently at the upper bound of efficacy.

Real-world evidence reinforces these trial findings. A 6-month retrospective cohort study using US electronic health record data (n = 2,396) found that tirzepatide-treated patients with obesity without diabetes achieved a mean weight reduction of -11.15% versus -8.83% with semaglutide (adjusted difference -2.32 percentage points; 95% CI: -3.17, -1.48), with higher proportions reaching 5%, 10%, 15%, and 20% weight-reduction targets. Greater reductions in BMI, blood pressure, and HbA1c were also observed with tirzepatide, and this comparative advantage was noted despite more semaglutide-treated patients receiving higher doses (≥1.7 mg: 67.7% vs. ≥10 mg tirzepatide: 42.4%). These findings are consistent with the SURMOUNT-5 trial results cited in the same study. For cardiovascular risk reduction in T2DM, observational data indicate that combining a GLP-1 receptor agonist with an SGLT2 inhibitor reduces major adverse cardiovascular events, hospitalization for heart failure, and all-cause mortality more than either monotherapy alone, with nine observational studies supporting this pattern across populations including those with atherosclerotic cardiovascular disease and heart failure.

The tolerability profile of these agents remains a clinically relevant differentiator. A Bayesian network meta-analysis of 48 RCTs (27,729 participants) identified tirzepatide as carrying the highest risk of nausea and diarrhea among GLP-1-based therapies in T2DM, while dulaglutide and lixisenatide showed the lowest GI risks. In non-diabetic populations, the meta-analysis of six RCTs reported nausea (RR 3.11; 2.74–3.54), vomiting (RR 5.94; 4.50–7.85), diarrhea (RR 2.92; 2.53–3.37), and constipation (RR 2.85; 2.38–3.42) with tirzepatide versus placebo; serious adverse events overall were not statistically significant (RR 0.93; 0.76–1.13), though serious GI events (RR 3.07; 2.03–4.66) and discontinuation due to adverse events (RR 2.29; 1.74–3.01) were. Notably, a systematic analysis of placebo-controlled incretin trials found that larger therapeutic efficacy was not systematically associated with higher GI adverse event or discontinuation rates, suggesting better tolerability of the more effective agents relative to their efficacy gains. Phase II and III data for emerging agents — including the GLP-1/amylin combination cagrilintide — suggest greater sustained weight loss than semaglutide monotherapy, positioning next-generation dual and multi-target analogs as the frontier of this therapeutic class.

CagriSema's Holistic Promise: Beyond Weight Loss in Metabolic Health

The latest data on CagriSema presented at EASD 2026 paints a compelling picture of a therapy poised to offer more than just significant weight loss and glycemic control. This investigational drug, a co-formulation of semaglutide and cagrilintide, is demonstrating a multi-faceted impact that could redefine expectations for metabolic health interventions.

A particularly noteworthy finding is the fMRI study, which provides objective evidence for CagriSema's ability to modify brain responses to high-calorie food cues. This translates clinically into a significant reduction in 'food noise,' cravings, and hunger – a subjective but critical experience for individuals struggling with overweight or obesity. Addressing this behavioral component at a neurological level could be a powerful differentiator, potentially leading to improved patient adherence and more sustainable weight management outcomes.

Beyond the brain, CagriSema shows impressive effects on body composition. Clinical data indicates significant reductions in abdominal, liver, and pancreas fat in patients with early type 2 diabetes. This is a crucial benefit, as ectopic fat accumulation in these organs is a key driver of metabolic dysfunction and associated comorbidities. By targeting these fat depots, CagriSema offers a more profound metabolic improvement than simply reducing overall body weight. Furthermore, the post hoc analysis suggesting maintained bone health with substantial weight reduction addresses a common concern with rapid weight loss, potentially offering a safety advantage in a market where bone density changes can be a consideration.

However, the path forward is not without its challenges. The landscape for obesity and type 2 diabetes treatments is increasingly competitive, with other potent GLP-1 RAs and dual agonists already on the market or in advanced development. CagriSema will need to demonstrate clear, sustained superiority or a highly differentiated value proposition to capture significant market share. Like other drugs in its class, gastrointestinal adverse events remain a common side effect, requiring careful patient management and titration strategies. While initial bone health data is promising, long-term studies will be essential to fully understand the sustained impact on bone mineral density across diverse patient populations. Ultimately, CagriSema's comprehensive profile suggests a significant potential to redefine treatment paradigms, offering benefits that extend across metabolic, behavioral, and structural health domains, but its success will hinge on robust long-term outcomes and effective market positioning.